Innovation Pharmaceuticals Inc (IPIX)

[Dr Jerry]

Most people in medicine know about the existence of defensin mimetic antibiotics but most have no idea that there is drug called Brilacidin that is a broad spectrum antibiotic with a long terminal half life and low toxicity and unheard of bacterial resistance.

Once the phase 2b data is unblinded there will be intensive interest from the medical/pharmacological communities if the data shows high efficacy at one time dosing.

I think Leo should entertain writing a piece to not just the medical community but he should address the main stream media like Scientific America and Time magazine.

Leo and Menon could one day be on the cover of Time Magazine for bringing to humanity a novel first in class broad spectrum antibiotic with no resistance potential.